|LETTER TO EDITOR
|Year : 2017 | Volume
| Issue : 1 | Page : 65
Triple-negative breast cancer: Positive factors
Rashmi Patnayak1, Amitabh Jena2
1 Department of Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
2 Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
|Date of Web Publication||17-Jan-2017|
Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati - 517 507, Andhra Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Patnayak R, Jena A. Triple-negative breast cancer: Positive factors. J Med Soc 2017;31:65
In India, the toll of death due to breast cancer is rising. A routine work-up for breast carcinoma includes evaluation of estrogen receptors, progesterone receptor, and human epidermal growth factor receptor-2/neu status for therapeutic consideration. Triple-negative cancers are those which are negative for the above-mentioned markers and hence do not respond to standard therapy. They are aggressive and tend to affect younger women <40 years. In a previous study, we found 22.7% cases to be triple negative.  Another study from Sharma et al. found 31.9% triple-negative breast cancers.  As mentioned in the editorial "What's positive about triple-negative breast cancers?" new therapeutic models are being tried for these subset of breast cancers.  Androgen receptor evaluation is one such method. Recently, we analyzed our data and found 20% triple-negative breast cancers showing positivity for androgen receptor [unpublished data]. We agree with the observation that androgen receptor has a crucial role to play in triple- negative breast cancers. The future for androgen receptor does hold promise as illustrated by the recent trials. 
Data from various centers of our country coupled with follow-up information will be valuable in determining the prognosis and in providing a targeted therapy for triple-negative breast cancer patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al.
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol 2015;36:117-22.
Sharma M, Sharma JD, Sarma A, Ahmed S, Kataki AC, Saxena R, et al.
Triple negative breast cancer in people of North East India: Critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev 2014;15:4507-11.
Laishram RS, Singh NS. What's positive about triple negative breast cancers? J Med Soc 2015;29:61-3.
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al.
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-12.